Clinical effect of fumarate on Hp positive peptic ulcer
LIU Xiaogang1, ZHANG Jiaojiao1, YANG Ting2, LIU Chengwen3
1. Department of Gastroenterology, the Second Affiliated Hospital of Air Force Military Medical University, Xi’an 710038, China; 2. Pharmacy Department of Shangluo Central Hospital, Shaanxi 726000, China; 3. Department of Gastroenterology, Xi’an Medical College, Xi’an 710021, China
Abstract：Objective To investigate the clinical effect of fumarate in the treatment of Helicobacter pylori (Hp) positive peptic ulcer (PU). Methods A total of 94 HP-positive PU patients from the gastroenterology outpatient department of the Second Affiliated Hospital of Air Force Military Medical University from May 2022 to April 2024 were selected and randomly divided into control group and study group with 47 cases in each group. The control group was treated with amoxicillin + bismuth colloid pectin + clarithromycin + omeprazole, while the study group was treated with amoxicillin + bismuth colloid pectin + clarithromycin + fumarate Vonorazine orally for 2 weeks. The ulcer healing, Hp eradication, clinical efficacy, gastric acid secretion function and safety of the two groups were compared. Results The ulcer healing rate of the study group was 93.62% (44/47) higher than that of the control group (78.72% (37/47), and the difference was statistically significant (P<0.05). Compared with the control group, the eradication rate of Hp in the study group was higher (87.23% vs. 68.09%, P<0.05). The total effective rate of the two groups was higher in the study group (82.29% vs. 95.74%, χ2=7.029, P<0.05). After treatment, basal gastric acid secretion (BAO), maximum gastric acid secretion (MAO) and peak gastric acid secretion (PAO) decreased in both groups. The BAO, MAO and PAO levels in the study group were (4.15±1.44) mmol/h, (8.02±2.13) mmol/h and (12.12±3.67) mmol/h lower than those in the control group (5.36±1.98) mmol/h, (10.15±2.99) mmol/h and (15.01±3.59) mmol/h (t=3.388, 3.978, 3.859, P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (4.26% vs. 10.64%, P>0.05). Conclusions The treatment effect of fumarate on Hp positive PU is excellent, which is worthy of promotion due to the promotion of ulcer healing, inhibition of gastric acid secretion and its safety.
Ren J, Jin X, Li J, et al. The global burden of peptic ulcer disease in 204 countries and territories from 1990 to 2019: a systematic analysis for the global burden of disease study 2019[J]. Int J Epidemiol, 2022, 51(5):1666-1676.
Katelaris P, Hunt R, Bazzoli F, et al. Helicobacter pylori world gastroenterology organization global guideline[J]. J Clin Gastroenterol, 2023, 57(2):111-126.
[15]
Chey W D, Mégraud F, Laine L, et al.Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and Europe: randomized clinical trial[J]. Gastroenterology, 2022, 163(3):608-619.
[16]
Qian H S, Li W J, Dang Y N, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of helicobacter pylori infection compared with bismuth-containing quadruple therapy[J]. Am J Gastroenterol, 2023, 118(4):627-634.
[17]
Liu L, Nahata M C. Vonoprazan with amoxicillin or amoxicillin and clarithromycin for the tTreatment of helicobacter pylori infection[J]. Ann Pharmacother, 2023, 57(10):1185-1197.
Simadibrata D M, Syam A F, Lee Y Y. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(12):2217-2228.
[20]
Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole[J]. Br J Clin Pharmacol, 2022, 88(7):3288-3296.
2025, Vol. 36 
